Trials / Completed
CompletedNCT03317457
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- AIO-Studien-gGmbH · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Durvalumab and Tremelimumab | immun checkpoint inhibitor |
| DRUG | Doxorubicin | Anthracycline |
Timeline
- Start date
- 2017-12-15
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
- First posted
- 2017-10-23
- Last updated
- 2023-06-15
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03317457. Inclusion in this directory is not an endorsement.